home / stock / apto / apto news

APTO News and Press, Aptose Biosciences Inc. From 05/25/22

Stock Information
Company Name: Aptose Biosciences Inc.
Stock Symbol: APTO
Market: NASDAQ
Website: aptose.com
Menu
APTO APTO Quote APTO Short APTO News APTO Articles APTO Message Board
Get APTO Alerts

News, Short Squeeze, Breakout and More Instantly...
APTO - Aptose to Provide Program Updates at KOL Webinar on Thursday, June 2nd

SAN DIEGO and TORONTO, May 25, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that it will host a key opinion le...
APTO - Aptose to Hold KOL Event and Corporate Update Thursday, June 2nd

Clinical Updates for HM43239 and Luxeptinib Poster Presentation for HM43239 is Scheduled for June 10th at EHA2022 Hybrid Congress SAN DIEGO and TORONTO, May 12, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (...

APTO - Aptose Biosciences Inc. (APTO) CEO Dr. William G. Rice on Q1 2022 Results - Earnings Call Transcript

Aptose Biosciences Inc. (APTO) Q1 2022 Earnings Conference Call May 9, 2022, 5:00 PM ET Company Participants Dr. William G. Rice – Chairman, President and Chief Executive Officer Dr. Rafael Bejar – Senior Vice President and Chief Medical Officer Dan Ferry – Managing Direc...

APTO - Aptose Biosciences GAAP EPS of -$0.12 beats by $0.02

Aptose Biosciences press release (NASDAQ:APTO): Q1 GAAP EPS of -$0.12 beats by $0.02. "We expect our research and development expenses to be higher for the foreseeable future as we continue to advance HM43239 and luxeptinib into larger clinical trials." "We expect that our general and adminis...
APTO - Aptose Reports Results for the First Quarter 2022

Expands HM43239 dose cohort at 160 mg Headway with luxeptinib “G3” formulation in patients Conference call and webcast at 5:00 pm ET today SAN DIEGO and TORONTO, May 09, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the &...

APTO - Notable earnings after Monday's close

ADES, AGM, AIV, AKBA, ALCO, ALTO, AMC, AMPH, AMWL, ANGI, APPF, APTO, ARCT, AROC, ASLE, ASRT, ATER, AVIR, AZTA, BATL, BHF, BLFS, BLI, BLNK, BODY, OTCPK:BOWFF, BRMK, BRT, BW, BWXT, CAPL, CARA, CARG, CHMI, CLAR, CLOV, CNNE, CSTL, OTCPK:CURLF, DDD, DHT, DNB, ENTA, EQH, EVBG, FCRD, FF, FGEN, FLL, ...

APTO - Aptose stock rises as HM43239 gets FDA fast track status to treat blood cancer subtype

The U.S. Food and Drug Administration (FDA) granted fast track designation to Aptose Biosciences' (NASDAQ:APTO) HM43239 to treat patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with FLT3 mutation. The company said the oral drug is currently being evaluated in an intern...
APTO - Aptose Receives Fast Track Designation for HM43239 in Relapsed/Refractory AML Patients and FLT3 Mutation

SAN DIEGO and TORONTO, May 04, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignan...

APTO - Aptose to Present at 2022 RBC Capital Markets Global Healthcare Conference

SAN DIEGO and TORONTO, May 03, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignan...

APTO - Luxeptinib Preclinical Data Extend Potential Applications from Oncology to Inflammation

SAN DIEGO and TORONTO, May 02, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignan...
Previous 10 Next 10